Sitemap
- Home
- Diabetes
- Integrated Diabetes Care
- Articles
- A narrative review for clinicians on insulin management for Type 2 Diabetes during Ramadan
- ATTD 2021: Patients’ profiles for digital tools
- Impact of Time-In-Range on Diabetes Management
- EVOLUTION: RWE from Saudi Arabia
- Time-In-Range (TIR): How to interpret it and how it is associated with outcomes
- Expert consensus statement on management of older adults with type 2 diabetes (T2D)
- The InRange Study
- The burden associated with insulin self-management
- Post-exercise hypoglycemia in relation to medication regimen among adults with type 2 diabetes
- Do historical HbA1c values explain glycemic legacy effect in type 2 diabetes?
- Titration Inertia; A Predominant Issue for People with Diabetes
- Challenges associated with commonly-used insulin advancement options
- What Is Time-in-Range?
- Unveiling Significance of Time in Range: Value as key Glycemic Biomarker
- Management of athletes and active people with diabetes - The American Medical Society for Sports Medicine (AMSSM) scientific statement
- Diabetes management during Ramadan
- Inside Diabetes: ATTD Edition | Type 2 Diabetes
- Understanding Time-in-Range: Assessment, Targets, and Benefits for Optimal Glycemic Control
- Time-in-Range: A Key Determinant of Quality of Life
- Need to redefine the treatment paradigm Post OAD
- The Evolving Role of Treatment and Technology in Diabetes Care
- Tools
- Events
- Articles
- Type 2 Diabetes
- Articles
- New Horizon in management of high-risk patients with Diabetes
- iGlarLixi Enables Safe Ramadan Fasting for Most T2D Patients
- SoliMix Study Results Summary
- New 2022 ADA/EASD Guidelines: GLPP-1 RA/Insulin Combination Is Recommended
- Effective Treatment Simplification
- Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial.
- Recommendations on treatment simplification of complex insulin regimens to improve clinical outcomes in patients with T2DM
- The ATOS Study: Real-World Study on Effectiveness of Insulin Glargine U300 in the Gulf Region.
- The SoliRam observational study
- ATTD 2021: Technology Supporting Initiation, Titration, and Intensification
- Groundbreaking SoliD Study: Comparative Efficacy of iGlarLixi and IDegAsp
- Glargine 300 use in people with type 2 diabetes who fast during Ramadan
- SoliD: Redefine Treatment Paradigm Post-OAD
- Advancing Therapy with iGlarLixi: Differentiation from other complex regimens
- Is Premixed Insulin an Effective Treatment for Type 2 Diabetes Uncontrolled by OADs?
- Resources
- Events
- Articles
- Other Diabetes Topics
- Type 1 Diabetes
- Articles
- Closed-loop insulin delivery during exercise in people with T1DM
- Summary of SAGE study on Adults with T1DM
- Why to screen for Autoimmune T1D
- How to screen for Autoimmune T1D
- Inside Diabetes: ATTD Edition | Type 1 Diabetes
- Edition Junior Study - Helping patients with type 1 diabetes (T1D) to find better treatment options
- Saudi Health Promotion and Prevention Guideline for Diabetes Mellitus
- The burden of Autoimmune T1D
- Understanding Autoimmune T1D disease & Different Stages
- T1D Treatment Practice and the SAGE Study
- Articles
- Integrated Diabetes Care
- Dermatology
- Atopic Dermatitis
- Articles
- The Cumulative Disease Burden of AD in Adult Patients
- The Hidden Impact of Cumulative Life Course Impairment (CLCI) in Dermatology: An Overview
- Long-Term-Impact-of-AD-and-the-Potential-benefits-of-early-intervention
- Improving Quality of Life in Patients with Uncontrolled Atopic Dermatitis (AD): Tools for Timely Identification and Treatment
- Atopic Dermatitis Pathophysiology: Breaking Down the Barrier
- Can Early Therapeutic Intervention Shape Disease Course in Pediatric AD
- Impact of Advanced Systemic Therapies on Disease Control in AD
- Type 2 Inflammation in Skin Tissue: Exploring Shared and Distinct Pathways in Prurigo Nodularis and Atopic Dermatitis
- The role of Epithelial Barrier Components in AD, insights and implications
- Inside Atopic Dermatitis: Burden on Patients
- Disease Modification Concepts in Atopic Dermatitis
- Can Early Intervention Shape the Course of Atopic Dermatitis
- Atopic Dermatitis in Children: High Burden and Limited Treatment Options
- What Could Remission Mean in Atopic Dermatitis
- IL4 and IL13 important role in Chronic Itch
- Mechanism of Action of Atopic Dermatitis
- AD and PN: Diagnosis and Impact on Quality of Life
- Association of Younger Age of Onset with Persistence of Atopic Dermatitis
- Factors Associated with Development of Atopic Comorbidities in AD
- Understanding Cumulative Disease Burden in Uncontrolled AD
- Unseen Burdens: How Cumulative Life Course Impairment (CLCI) Affects Patients with Moderate-to-Severe Atopic Dermatitis (AD)
- Inside Atopic Dermatitis: Burden on the Healthcare System
- Tools
- Events
- Articles
- Asthma
- Articles
- Dupilumab improves clinical outcomes in patients with severe asthma compared to other biologics
- LIBERTY ASTHMA QUEST Trial: Dupilumab Efficacy in Type 2 Asthma Patients on High-Dose ICS
- LIBERTY ASTHMA QUEST Trial: Dupilumab Efficacy in Eosinophilic (≥500 cells/µL) and Allergic Asthma Subgroups
- LIBERTY ASTHMA QUEST Trial: Dupilumab Evidence Summary in Moderate-to-Severe Uncontrolled Asthma
- LIBERTY ASTHMA TRAVERSE Trial: Long-Term Safety and Efficacy of Dupilumab in Moderate-to-Severe Asthma
- Articles
- Bullous Pemphigoid
- Articles
- Patient morbidity and mortality in BP
- Treatments and challenges for bullous pemphigoid
- Considerations for bullous pemphigoid management
- What is Bullous Pemphigoid
- Bullous Pemphigoid Mechanism of Disease Animation Storyboard
- Bullous Pemphigoid Burden of Disease and Diagnosis
- Pathophysiology of Bullous Pemphigoid
- Articles
- Prurigo Nodularis
- Articles
- Mechanism of Prurigo Nodularis Disease
- There is significant unmet need in the management of PN¹
- Practical Approach in Understanding PN Pathophysiology
- Type 2 Inflammation may play a role in Prurigo Nodularis Pathophysiology¹
- Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials
- The Pathophysiology of Prurigo Nodularis
- PN Expert Interview Series with Dr. Shawn Kwatra
- Prurigo Nodularis is a distinct, Chronic, Neural and Immune- Mediated skin disease characterized by intense itch and Nodular Lesions¹
- Articles
- Eosinophilic esophagitis
- Chronic Spontaneous Urticaria CSU
- Atopic Dermatitis
- Cardiology
- Other Cardiology Topics
- Resources
- Act Now for your ACS Patients
- MyPal Support Program
- 556/146 for Lipid Management after ACS
- MyPal Support Program
- Are You Ready for 146? Achieving Optimal LDL-C Levels
- Exploring the 556/146 Concept: Insights from Leading Experts
- Understanding the 556/146 Concept: Insights from Leading Experts
- How to Inject Praluent Once-Monthly 300 mg Pen?
- Why Praluent is the Optimal Choice for Post-ACS Patients?
- Are You Ready for 556? Achieving Critical LDL-C Targets
- How to Inject Praluent 75/150 mg Pen?
- Resources
- Dyslipidemia
- Articles
- Cardiovascular diseases (CVDs) are the leading cause of death globally¹
- Approach for Patients with PAD and T2D: Focus on LDL-C Control
- Identifying and treating patients with high Lipidaemia risk post-ACS
- Atherosclerotic Cardiovascular Disease Risk Assessment
- APSC Consensus Recommendations on Dyslipidemia
- ESC/EAS 2019 international guidelines
- Lp(a) as ASCVD risk factor
- Public health recommendations for Lp(a) measurement
- Relationship Between LDL-C LLTs and Risk of Stroke
- Lipid Management in Patients with Diabetes Mellitus
- Should we encourage earlier and broader use of combination therapies in dyslipidemia?
- Prospective evaluation of lipid management following acute coronary syndrome in Saudi Arabia
- Lipid management in patients with ACS/ASCVD
- Cardiovascular Disease in Saudi Arabia: Facts and the Way Forward
- Improving Lipid Management for Patients Post-ACS
- Possible Challenges Post One Year of ESC/EAS Guidelines
- Approach for Patients with CAD: Focus on LDL-C Control
- Overview of adherence data with LLT highlighting the most recent data with PCSK9i
- ACC/AHA vs ESC/EAS LDL–C recommendations for residual risk reduction in ASCVD: A simulation study from Da Vinci
- Achievement of lipid modification goals with Statins & Ezetimibe
- Atherosclerosis: Identifying risks and improving outcomes
- Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)
- Resources
- Events
- Articles
- Thrombosis
- Articles
- Independent Risk Factors for Venous Thromboembolism
- Risk for Pulmonary Embolism Continues Beyond 6 Weeks of Surgery
- Trends in Pulmonary Embolism-related mortality in Europe
- Evaluation Of Comparative Efficacy and Safety of Thromboprophylaxis Agents Among Critically Ill Patients
- Sanofi Thrombosis Summit
- Benefit of Prophylaxis for High-Risk Surgical Patients
- Global use of RAM and Thromboprophylaxis in hospitalized patients
- Prolonged Thromboprophylaxis with LMWH after Abdominal or Pelvic Surgery
- VTE Prophylaxis in Surgical Patients
- Maternity Clot Risk Model to Predict Women at Risk of VTE
- Evaluation Of Comparative Efficacy and Safety of Thromboprophylaxis Agents Among Critically Ill Patients
- Specific Patient Characteristics Linked to Below Average Quality of Life in Patients with Recent Venous Thromboembolism (VTE)
- Caprini Score Responses to Prevent VTE in Patients Undergoing Varicose Vein Surgery
- Events
- Articles
- Hypertension
- Other Cardiology Topics
- Vaccines
- Respiratory Syncytial Virus
- Articles
- RSV
- RSV Burden in Infants
- Epidemiology and Healthcare Burden Attributable to Laboratory-Confirmed RSV Cases Among Children Under Five Years Old in Saudi Arabia
- Implementing Beyfortus successfully
- Beyond High-Risk: Expanding RSV Protection for Newborns and Infants
- Healthcare Resource Utilization and Direct Medical Costs of RSV Infection in Children Under Five Years in Saudi Arabia
- New horizon of RSV lower respiratory tract disease LRTD in infants: Reflection on two seasons of prevention
- RSV Burden in Jazan
- Healthcare Utilization and Economic Burden of Pediatric Lower Respiratory Tract Infections Across Five Tertiary Hospitals in Saudi Arabia
- Nirsevimab RWD Metanalysis
- Rattle
- 2024 RSV International Congress - ESPID
- Real-World Effectiveness of Nirsevimab
- Beyfortus in Action ECMMID
- RSV History
- Implementing Beyfortus successfully (ES)
- Epidemiological Characteristics of RSV
- Implementing Beyfortus successfully (US)
- RWE data on Nirsevimab and RSV preF vaccine
- Saudi initiatives on Bronchiolitis Recommendations
- Nirsevimab : Clinical Experience
- Kuwait taking the lead in RSV protection for all infants in the Middle east
- 2024 RSV International Congress ECMMID
- Healthcare Utilization and Economic Burden of RSV Infections Among Children Under 5 Years in Saudi Arabia
- Ensuring overall RSV prevention in every individual
- Nirsevimab FAQs
- Beyfortus®, an innovative immunization
- Nirsevimab International Recommendation
- Implementing Beyfortus successfully (FR)
- Burden of Disease
- Saudi National immunization strategy for RSV prevention
- Beyfortus in Action
- All Infant Protection
- Real World Evidence Impact of universal immunization with Nirsevimab
- Resources
- Articles
- Influenza
- Mass Gathering
- Respiratory Syncytial Virus
- Neurology
- Multiple Sclerosis
- Articles
- Exercise as ”medicine” in the treatment of MS
- MS Pulse Reels
- How old is your brain?
- MS Updates
- Understanding Kaplan–Meier Curves in MS: An Overview with Dr. Barry Singer
- Inside MS: Explore how BTK drives immune cell activation and CNS damage
- Smoldering Neuroinflammation
- Cognitive decline – The invisible burden of MS?
- Slowing of brain atrophy with Teriflunomide
- Why has our brain suddenly become of interest?
- Measuring brain atrophy. What can be done and where are we heading?
- The importance of deep grey matter in MS
- MS pulse Reels - How to Track MS | Acknowledge, Assess, Advocate
- Falling chronically ill – How do I cope and move forward?
- Understanding 6‑Month CDP in MS: An Overview with Dr. Barry Singer
- Understanding PIRA in MS: An Overview with Dr. Barry Singer
- The reason for MS – beyond focal inflammation
- Thalamic atrophy as a new biomarker of MS? The predictive value and how to use in clinical practice
- Cognitive training – A curse or a blessing?
- MS Pulse Reels - MS Monitoring in Practice | Turning Tracking into Action
- MS pulse Reels - See the Bigger Picture: Why Tracking Matters
- Tolebrutinib Direct Effects on Myeloid Cells in PwMS
- Discover the science behind Tolebrutinib: a BTK inhibitor designed to slow MS disability progression by modulating adaptive and innate immunity
- A promising biomarker in MS: Neurofilament light chain
- Events
- Multiple Sclerosis Diagnosis and Misdiagnosis by Prof. Bassem Yamout
- Aubagio® - Impact on Brain Health and Real World Efficacy by Dr. Ahmed Shatila
- MSXChange l MS and Women
- Advancing the Standard of Care: Addressing Progression in MS
- Personalized Therapy in RMS - Which DMT to Use and When? Professor Peter Rieckmann
- Intro to Multiple Sclerosis by Dr Naji Riachi
- The Underlying Biology of Neuroinflammation
- A Patient's Journey on Teriflunomide: insights into Long-Term Treatment
- MS pulse - Tracking the hidden drivers of MS progression
- Articles
- Epilepsy
- Multiple Sclerosis
- Rare Disease
- Gaucher
- Articles
- Gaucher Biochemistry Diagnosis support
- Gaucher Mechanism of Disease
- When Hematological Signs Lead the Diagnosis
- The Enlarged Spleen Mystery
- Diagnostic Algorithm for Gaucher Disease in Adult
- Bone Monitoring Guidelines in Gaucher Disease Video
- Gaucher Haematology Diagnosis support
- Diagnostic Algorithm for Gaucher Disease in Pediatric
- Gaucher
- Understanding Gaucher Disease Type 3
- The Role of Pediatrician in Gaucher Disease
- Gaucher Neurology Diagnosis support
- Events
- Articles
- Fabry
- Articles
- BIOCHEMICAL DIAGNOSTIC STRATEGY IN FEMALES SUSPECTED OF FABRY DISEASE
- DIAGNOSING FABRY DISEASE IN CLINICAL PRACTICE
- When the Heart, Kidneys, and Nerves Intersect
- Tolerability of Accelerated Agalsidase Beta Infusions in Fabry Disease: The SHORTEN Study Analysis
- ROLE OF ECG IN DIFFERENTIAL DIAGNOSIS OF ANDERSON–FABRY DISEASE WITH HCM
- Fabry Disease in Cardiology Practice: From Red Flags to Diagnosis
- Better care for Fabry
- Fabry Disease from Cardiology Perspective
- Renal Outcomes After Switching to Agalsidase Beta: A Single-Center Analysis
- From Registry to Reality: Reduced Stroke Incidence with Agalsidase Beta in Fabry Disease
- Structured Monitoring for Early Detection of Fabry Progression
- Fabry
- Events
- Articles
- Other Rare Disease Topics
- Articles
- An overview of Lysosomal Storage Disorders & Sanofi`s Commitment to the Development and Provision of Treatments
- The role and importance of Patients Associations and Scientific societies ; Oman Experience
- Legacy Video for Rare Disease Academy
- Multidisciplinary approaches in Rare Disease Patient management
- LSDs overview
- The role and importance of Patients Associations and Scientific societies ; UAE experience
- Every Moment Matters: Navigating Diagnosis of Fabry Disease
- What are the new diagnostics modalities used to expedite Rare Disease patients identification?
- Extraordinary measures: what are the benefits to have such movies talking about Rare Diseases?
- What is the role of Artificial Intelligence in accelerating patient's diagnosis?
- Meet a Sanofi Specialist
- How To Diagnose LSDs?
- What are Lysosomal Storage disorders?
- Lysosomal Storage Diseases from Neurology Perspective
- Multidisciplinary approaches in Rare Disease Patient management in KSA
- When shall we think of a rare disease from Neurological perspective
- The Stigma of Rare Diseases
- Events
- Articles
- Mucopolysaccharidosis Mps
- Acid Sphingomylenase Deficiency Niemann Pick
- Articles
- Inspiring Stories of Patients Living with ASMD
- What is ASMD?
- Respiratory Impairment in Acid Sphingomyelinase Deficiency (ASMD): A Case Report.
- Professor Moeen Al Sayed video on ASMD
- How is ASMD inherited?
- Impact of symptoms and risk of ASMD on patients and caregivers
- Differential diagnostics for ASMD in patients suspected to have GD
- Professor Tawfeq Ben Omran video on ASMD
- Management of ASMD - Expert opinion: Professor Tawfeq Ben Omran
- Uncover ASMD and GAUCHER
- ASMD
- Management of ASMD - Expert opinion: Professor Fatma Al- Jasmi
- Management of ASMD - Expert opinion: Professor Moeen Al Sayed
- Professor Fatma Al-Jasmi video on ASMD
- What Are the Signs and Symptoms of ASMD?
- How do you know if you or a loved one has ASMD?
- Consensus Guidelines for the Clinical Management of ASMD
- ASMD Phenotypes
- Events
- Articles
- Pompe
- Articles
- Expert Group Consensus From the Arabian Peninsula On the Diagnosis of Lopd
- Expert Group Consensus From The Arabian Peninsula On The Diagnosis Of Late Onset Pompe Disease for orthopedists
- When Weakness Tells a Bigger Story
- IOPD Challenges
- What makes avalglucosidase alfa different from alglucosidase alfa in terms of clinical efficacy and patient outcomes?
- Early diagnosis and management of IOPD
- Pompe Care Podcast Series
- Expert Group Consensus From the Arabian Peninsula On the Diagnosis of Lopd
- Prevalence Of LOPD In Patients With Undifferentiated Proximal Myopathy And Undiagnosed Muscle Biopsy
- What factors influence your decision to switch a patient from alglucosidase alfa to avalglucosidase alfa?
- Have you observed any significant differences in treatment outcomes between these two therapies in your local practice?
- Diagnostic challenges of LOPD
- The Many Faces of Limb-Girdle Weakness
- Pompe
- Long-term Safety and Efficacy of Avalglucosidase Alfa IN Patients with Late-Onset Pompe Disease (NEO-EXT)
- Have you considered Pompe Disease?
- Pompe video
- Their Stories shaped them like Pearls
- Pompe Care Podcast Series 2
- What challenges do clinicians face in monitoring in disease progrission and response to therapy?
- How has avalglucosidase alfa impacted the treatment paradigm for both infantile-onset and late-onset Pompe disease in your experience?
- Expert Group Consensus From The Arabian Peninsula On The Diagnosis Of Late Onset Pompe Disease (LOPD)
- Social stigma
- Thank You!
- Differential Diagnosis Of Late Onset Pompe Disease (LOPD) and Myotonic Dystrophy Type 1 Through Abdominal Ultrasonography
- Safety and efficacy of Avalglucosidase Alfa versus Alglucosidase Alfa in patints with Late-Onset Pompe Disease (COMET): a phase 3, randomized, multicentral study results
- What has been your experience with switching patients from alglucosidase alfa to avalglucosidase alfa?
- How can you see changing the lives of patient starting taking Nexviazyme and if you can share from your experience couple of patient stories that realy impacted positively from staring the treatment for Pompe disease?
- Experts recommendations on Late Onset Pompe Disease (LOPD) differential diagnosis from GCC
- Navigating the Pompe Disease Journey
- Pompe Care Podcast Series 3
- Articles
- Lysosomal Storage Disorders (LSD)
- Gaucher
- Other topics
- Payor
- Articles
- cGVHD Burden
- Rezurock Efficacy
- Unmet Needs
- Proven Safety of Dupixent® against Type 2 Inflammation
- Unmet Need
- Economic Burden of COPD in KSA
- AT1D Disease Overview
- Tzield MOA and Dosing
- Rezurock Dosage
- AT1D Early Detection
- Tzield Efficacy and Safety
- Proven Efficacy of Dupixent® against Type 2 Inflammation
- Burden of AT1D
- Rezurock Economic Value
- Clinical Burden of COPD
- Rezurock Safety
- Burdens of CSU
- Proven Efficacy of Dupixent® in COPD
- Articles
- Immunology Pipeline
- Payor
- Respiratory
- Asthma
- Articles
- FeNO Video
- Dupixent® (dupilumab) Mechanism of Action
- What gives you confidence that Dupixent improves patients’ quality of life?
- OCS Video
- Pediatric Management
- Consider Dupixent for Asthmatic patients with high EOS
- Severe Asthma Biomarker's
- Discover a solution to control mixed Eosinophilic and Allergic Asthma
- About Type 2 Inflammation – Asthma
- Understanding Airway Obstruction: The Role of Mucus Plugging in Asthmatic Disease
- FeNO Is a Clinically Useful Biomarker of Type 2 Inflammation in Pediatric Patients With Asthma
- How do you choose the right Biologic for a particular Asthma patients?
- What's possible when their Child's Asthma is under control?
- Airway Hyperresponsiveness in Asthma
- What is your experience with Dupixent in your practice?
- Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction
- Consider Dupixent for Asthmatic patients with OCS use
- VESTIGE Trial Results: Dupilumab in Type 2 Asthma
- IL-4/IL-13 Dual Cytokine Signaling in Severe Asthma: Mechanistic Insights by Prof. Kenneth Chapman
- Lung Function Decline and Exacerbation in Asthma
- IL-4, IL-13, AND IL-5 ARE DRIVERS OF SYSTEMIC TYPE 2 INFLAMMATION
- VESTIGE study
- Clinical Remission Video
- Articles
- Chronic Rhinosinusitis With Nasal Polyps Crswnp
- Chronic Obstructive Pulmonary Disease (COPD)
- Articles
- GOLD Recommendations for Treatment and Management of COPD
- A deeper look at the inflammation behind exacerbations in COPD
- GOLD 2026 Report: Key Updates for COPD Management
- A deeper look at the inflammation behind exacerbations can IGNITE NEW THINKING IN COPD
- Clinical Indicators of COPD: A GOLD Guidelines Review
- What tests can help diagnose and monitor your patients with COPD?
- Articles
- Asthma
- Rare Blood Disorders
- Gastroenterology
- Eosinophilic esophagitis
- Articles
- Importance of assessing key disease domains in EOE
- Adaptive Eating Behaviors in EoE
- Understanding Eosinophilic Esophagitis (EoE)
- EOE Pediatric - Unmasking the Hidden Symptoms
- Pediatric EoE: Indicators for Early Diagnosis and Intervention
- Measures of Disease Severity in Eosinophilic Esophagitis (EoE)
- EoETaly Guidelines Part-2
- EoETaly Guidelines Part-1
- Articles
- Eosinophilic esophagitis
- Oncology
- Multiple Myeloma
- Articles
- Multiple Myeloma: Chromosome 1q+ cytogenetic abnormalities
- Minimal Residual Disease
- Multiple Myeloma: Elderly Patients
- Multiple Myeloma: Minimal Residual Disease
- Lenalidomide Refractory Patients
- MRD FAQs
- Myeloma Facts
- True Cost of Multiple Myeloma
- The Future of MRD
- About MRD
- Importance of MRD
- Multiple Myeloma: Renal Impairment
- Experts Perspective
- Multiple Myeloma: High Risk Cytogenetics
- Transform Myeloma
- Patients Factors & Impacts
- Articles
- Multiple Myeloma
- Transplant
- chronic GRAFT-VERSUS-HOST DISEASE (cGVHD)
- Articles
- Molecular Pathway
- Between The Lines: GVHD, Episode 1 – Understanding the Foundation of Graft vs Host Disease
- GvHD in Focus Risk Factors and Symptoms
- Tandem Meetings Transplantation and Cellular Therapy Meetings of ASTCT® and CIBMTR®
- Inflammation and Fibrosis Role
- European Respiratory Society (ERS)/ European Society for Blood and Marrow Transplantation (EBMT) clinical practice guidelines on treatment of pulmonary cGvHD in adults
- Treatment under Clinical Development
- Impact on Patients
- Other Treatment Options
- TANDEM Meeting 2026
- Psychological & Economical impact
- Understanding cGVHD
- Clinical outcomes of cGvHD following allogeneic HSCT: A Swedish population-based real-world registry study
- Optimizing Treatment
- Updated European Society of Blood and Marrow Transplantation consensus recommendations for GVHD prophylaxis and management in hematological malignancies after stem-cell transplantation
- GvHD Unpacked: A Guide to Classifications and Mechanisms
- Advances in the biology of chronic GVHD
- The Congress Connection: cGvHD and Transplant Key Takeaways in 2025
- Between The Lines: GVHD, Episode 2–Skin Manifestation of GVHD – A multidisciplinary Perspective
- Articles
- Transplant
- chronic GRAFT-VERSUS-HOST DISEASE (cGVHD)
- Rhinology
- Allergic Fungal Rhinosinusitis
- Chronic Rhinosinusitis With Nasal Polyps Crswnp
- Articles
- EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP
- Loss of Smell Improvement in Patients With CRSwNP
- IL-4 and IL-13 are key and central cytokines with unique and overlapping roles contributing to the pathophysiology of CRSwNP
- Loss of Smell Is a Key Symptom in CRSwNP
- Daily Burden of CRSwNP
- Articles
- Products
- Dupixent® Nasal Polyps
- Nexviazyme®
- Dupixent® Asthma
- Xenpozyme®
- Soliqua®
- Cerezyme®
- Aldurazyme®
- Cablivi®
- aTTP Sphere Digital Case Library
- Real-World Evidence Studies
- REACT-2020 and Aggregated Analysis
- aTTP-Related Events
- aTTP Diagnosis and Treatment
- Real World Evidence Studies/Spanish
- Real World Evidence Studies/Italian
- Delay in CABLIVI Start
- aTTP Sphere Digital Case Library - Kuwait
- CABLIVI Mechanism of Action
- Mechanism of Disease
- Recurrences
- Post-HERCULES
- ISTH TTP Guidelines
- HERCULES Study
- TTP Patient Case Study in UAE by Dr Hasan
- Delay in CABLIVI Start - Patient Outcomes
Watch ITTP patient shares his road to diagnosis of TTP and how healthcare professionals can further help patients and care partners
- HERCULES: Summary2
- TTP Patient Case Study in KSA
- Active Disease
- TTP Patient Case Study in UAE by Dr Hani Osman
- aTTP Sphere Digital Case Library - Qatar
- ISTH TTP Guidelines
- Healthcare Resource Utilization
- CABLIVI Safety Profile
- HERCULES STUDY
- Platelet Count Normalization
- CNR-MAT Registry Study
- Early Treatment Initiation
- CABLIVI-Specific Treatment Recommendation1
- Qfitlia™ (fitusiran)
- Rezurock®
- Aprovasc®
- Xatral®
- Sarclisa®
GMMG-HD7: the first phase 3 trial to assess the value of adding an anti-CD38 to VRd for induction alone, regardless of maintenance
ICARIA-MM: Addition of SARCLISA to Pd Extended Median PFS to Nearly 1 Year
IMROZ: the only trial to evaluate an anti-CD38 +VRd therapy in 100% transplant-ineligible population.
Dosing & Administration
IKEMA: mPFS of 3 years with SARCLISA + Kd is longest ever reported for anti-CD38 therapy in a pivotal trial that included lenalidomide-refractory patients
Mechanism of Action
- Solian®
- Myozyme®
- Dupixent® COPD
- Dupixent® Eosinophilic Esophagitis
- Fabrazyme®
- Beyfortus®
Decoding RSV unveiling truths and myths in infant burden
International Recommendation
Beyfortus in Action: Real-world data from the 2023-2024 RSV season
Beyfortus®, an innovative immunization for RSV disease prevention in infants
Real world evidence
Beyfortus, an innovative immunization for RSV disease prevention in infants
Nirsevimab International Recommendation
Clinical Experience
Implementing Beyfortus successfully: Practical insights from Spain
Conferences
- Dupixent® Atopic Dermatitis
- Qfitlia®
Qfitlia Prescriber Safety Brochure
Mechanism of action: how QfitliaTM (fitusiran) helps restore hemostasis by lowering antithrombin for people with hemophilia1
Manage breakthrough bleeds with reduced doses and frequency of factor or BPA1*†
QfitliaTM (fitusiran) offers proven bleed protection with as few as 6 injections a year1
Dosing for Qfitlia™ (fitusiran) is guided by antithrombin levels1
QfitliaTM (fitusiran): ATLAS clinical trial design
Qfitlia HCP Bleed Management Guidance (BMG)
Qfitlia AT Measurement and Dosing Guide
Safety information and adverse events on QfitliaTM (fitusiran)
INTERACTIVE DOSING TOOL FOR QFITLIATM
- Renvela®
- Dupixent® Prurigo Nodularis
- Tzield®
- Praluent®
- Toujeo®
- Toujeo for a Peaceful Ramadan
Campus Always On - Toujeo vs Degludec- Clinical Insights from the BRIGHT study for Insulin selection
Always On
- Innovation
Campus Always On - The Kidney-Diabetes Relationship: Clinical Use of Toujeo® (insulin glargine 300 U/mL) in People with CKD
- Guidelines
- Wall of Evidence
- How to Start
- Deliver-G
New Findings on Toujeo® for T2D Management Following Dual GIP-GLP-1 RA Therapy
- Guidelines
Evolving Basal Insulin Therapy: From First-Generation to Second-Generation Analogues in Diabetes Care
- Toujeo® Time in Range
Timely insulin initiation to limit disease progression
- Edition Junior
Campus Always On - Toujeo and GLP1s - Optimising Glycemic Control in Uncontrolled T2D
Campus Always On - How to Start People with Diabetes to Toujeo
- Type-1 Meta Analysis
- UltraFlexi-1
- Efficacy & Tolerability
Meet the Expert
Second generation basal insulin in advancing T2D therapy
- OneCare
- To help you manage your patients with T1DM
Campus Always On - Bridging the Glycemic Gap - Timely Transition from OADs to Toujeo
- Toujeo T2DM
- Clexane®
- Aubagio®
- Acid Sphingomylenase Deficiency Niemann Pick
- Fabry
- Immune Thrombocytopenic (ITP)
- Type 2 Diabetes
- Bullous Pemphigoid
- Pompe
- Prurigo Nodularis
- Gaucher
- Epilepsy
- Asthma
- Dyslipidemia
- Multiple Myeloma
- Other Rare Disease Topics
- Mass Gathering
- Chronic Rhinosinusitis With Nasal Polyps Crswnp
- Other Cardiology Topics
- Multiple Sclerosis
- Atopic Dermatitis
- Mucopolysaccharidosis Mps
- Hypertension
- Type 1 Diabetes
- Other Diabetes Topics
- Acquired Thrombotic Thrombocytopenia Purpura aTTP
- chronic GRAFT-VERSUS-HOST DISEASE (cGVHD)
- Eosinophilic esophagitis
- Immunology Pipeline
- Lysosomal Storage Disorders (LSD)
- Chronic Spontaneous Urticaria CSU
- Thrombosis
- Transplant
- Meningococcal disease
- Payor
- Chronic Obstructive Pulmonary Disease (COPD)
- Hemophilia A
- Integrated Diabetes Care
- Respiratory Syncytial Virus
- Influenza
- Scientific Content
- Sitemap
- Sign Up
- Sign In
- Legal notice
- Privacy Policy
- Cookie Policy